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Abstract
Metabolic adaptation is considered an emerging hallmark of cancer, whereby cancer cells exhibit high rates of
glucose consumption with consequent lactate production. To ensure rapid efflux of lactate, most cancer cells
express high levels of monocarboxylate transporters (MCTs), which therefore may constitute suitable therapeutic
targets. The impact of MCT inhibition, along with the clinical impact of altered cellular metabolism during prostate
cancer (PCa) initiation and progression, has not been described. Using a large cohort of human prostate tissues
of different grades, in silico data, in vitro and ex vivo studies, we demonstrate the metabolic heterogeneity of
PCa and its clinical relevance. We show an increased glycolytic phenotype in advanced stages of PCa and its
correlation with poor prognosis. Finally, we present evidence supporting MCTs as suitable targets in PCa, affecting
not only cancer cell proliferation and survival but also the expression of a number of hypoxia-inducible factor
target genes associated with poor prognosis. Herein, we suggest that patients with highly glycolytic tumours have
poorer outcome, supporting the notion of targeting glycolytic tumour cells in prostate cancer through the use of
MCT inhibitors.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Changes in cellular metabolism have recently emerged
as a hallmark of cancer [1,2] leading to an increase in the
number of novel therapies targeting cancer metabolism
[3–5]. Fluorodeoxyglucose positron emission tomogra-
phy (FDG-PET) for malignancy has been introduced as
a technique for metabolic imaging, based on the fact that
cancer tissue consumes a large amount of glucose as an
energy source and fluorodeoxyglucose [I8F] enters can-
cer cells through the same transport route as glucose.
However, there appears to be a consensus that FDG-PET
is not particularly useful for the detection or metabolic
grading of PCa, suggesting that in PCa, contrary to
other malignant neoplasms, glucose consumption is not
directly associated with malignancy [6]. However, some
studies have reported that the accumulation of FDG in
the prostate is higher in advanced stages of PCa, rather
than in early stages [7]. Although much of metabolic
cancer research focuses on the role of glycolysis, it
has recently become apparent that the tricarboxylic acid
(TCA) cycle and oxidative phosphorylation (OXPHOS)
also have major roles in many cancer types, includ-
ing prostate [8–12]. These data indicate that PCas may
exhibit unique metabolic profiles; however, the clinical
impact of these metabolic profiles is not known.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
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Previous work has suggested a role for monocar-
boxylate transporters (MCTs) at the diagnostic and
prognostic level in PCa [13–16]. MCTs are transmem-
brane proteins involved in the transport of important
monocarboxylates, such as lactate, and it has been
reported that most cancer cells express high levels of
MCTs to ensure rapid efflux of the lactate produced
[17]. They facilitate the efflux of lactate while they
also contribute to the preservation of intracellular pH,
by co-transporting a proton [18]. MCTs have been
recently explored as targets for cancer therapy [19–22].
Kim et al [23] reported an increased necrotic fraction
with no variations in prostate tumour volume following
MCTs inhibition; however, these results were obtained
using α-cyano-4-hydroxycinnamate (CHC), which is a
non-specific inhibitor of lactate transport.
Here, we detail the expression of MCTs as well as the
expression of a wide range of glycolysis-related proteins
in a large cohort of human prostate samples, including
metastatic PCa and across different in vitro models of
PCa progression, and demonstrate the impact of MCTs
inhibition in PCa cells in vitro and ex vivo.
Materials and methods
Patient samples and tissue microarray construction
Samples, including 203 non-neoplastic, 176 high-grade
prostatic intraepithelial neoplasia (PIN) and 480 neo-
plastic tissues were organized into tissue microarray
blocks (TMAs). Benign samples from 12 patients under-
going radical cystoprostatectomy and 10 metastatic PCa
cases were obtained from clinical biopsy samples. The
present study was previously approved by the local eth-
ical review committee.
Immunohistochemistry (IHC) staining and analysis
IHC technique was performed according to the informa-
tion given in Table 1, as previously described [9]. For
each treatment group (vehicle or drug), a total number
of 30–50 randomly chosen images were used for the
analysis.
Western blot analysis
Western blot analysis was performed for protein expres-
sion using antibodies (Santa Cruz Biotechnology, CA,
USA) for MCT1 (sc-365501, 1:500 dilution), MCT4
(sc-50329, 1:500 dilution), Actin (sc-1616, 1:5000 dilu-
tion), TOM20 (sc-11415, 1:5000 dilution) and UCP-2
(sc-6525, 1:400 dilution).
Cell culture and drugs
Prostate cell lines were obtained from the American
Type Culture Collection (ATCC, Manassas, VT, USA).
R1881 (Sigma, Gillingham, Dorset, UK) was used at a
concentration of 1 nM. For hypoxia treatment, cell cul-
tures were incubated in 1% O2. For experiments using
lactate, cells were exposed to 10mM sodium L-lactate,
a concentration that corresponds to the level of lactate
most commonly detected in human tumours [11].
siRNA transfection
siRNAs were purchased from Qiagen (Manchester,
UK) (Table 2) and transfected using Lipofectamine
RNAiMAX (Invitrogen, Life Technologies, Paisley,
North Renfrewshire, UK). Final siRNA concentrations
of 10 nM were used.
Metabolic profiling (extracellular glucose
and lactate measurements)
Cells were plated in 24-well plates until confluent. Glu-
cose consumption and lactate production were quanti-
fied before and after treatment using commercial kits, as
previously described [12].
ECAR and OCR measurements
ECAR reflective of the rate of glycolysis, and OCR,
reflective of the rate of OXPHOS, were measured using
a Seahorse Bioscience (Copenhagen, Denmark) XF24
analyser. Cells were plated in Seahorse XF24 plates and
incubated for 48 h. For knockdown experiments, cells
were transfected with the indicated siRNAs overnight
before treatment.
Analysis of cell respiratory efficiency
The activity of the mitochondrial complex I (NADH:
ubiquinone oxidoreductase) was evaluated enzymati-
cally using the Complex I Enzyme Activity Microplate
Assay Kit (ab109721, Abcam, Cambridge, UK), accord-
ing to the manufacturer’s instructions. The global cellu-
lar ATP levels were quantified using a Luminescent ATP
Detection Assay Kit (ab113849, Abcam).
Cell proliferation and viability assay
Reverse transfection was carried out on the day of seed-
ing. Cell number and viability were determined using
a Beckman Coulter™ (High Wycombe, Bucks, UK)
Vi-Cell.
Cell-cycle analysis
Adherent cells were fixed with ice-cold 70% ethanol and
incubated with 50 μg/ml propidium iodide and 10 μg/ml
RNaseA in phosphate-buffered saline (PBS) for 30min
at 37∘ in the dark. Propidium iodide staining inten-
sity was detected by flow cytometry (BDFacsCalibur,
Oxford, UK).
Quantitative real-time PCR (qRT–PCR)
For RNA isolation, the RNeasy Plus Mini Kit (Qiagen)
was used according to the manufacturer’s instruc-
tions. cDNA was synthesized using a High Capacity
cDNA Reverse Transcripton Kit (Applied Biosystems,
Life Technologies, Paisley, North Renfrewshire, UK).
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Table 1. Details of the immunohistochemical procedure used to analyse the expression of different proteins in human prostate samples
Positive Detection
Protein Antibody Company Antibody dilution control Incubation period system
MCT4 sc-50329 Santa Cruz
Biotechnology
1:500 Colon tumour Overnight R.T.U. Vectastain Universal
Elite ABC Kit, Vector, EUA
GLUT1 ab 15309 Abcam 1:2000 Head and neck tumour
CAIX ab 15086 Abcam 1:2000 Stomach
MCT1 sc-365501 Santa Cruz
Biotechnology
1:500 Colon tumour Overnight R.T.U. Vectastain Universal
Elite ABC Kit, Vector, EUA
HIF-1α 610958 BD Biosciences 1:100 Glioblastoma
LDH5 ab 53010 Abcam 1:1000 Colon tumour 2 h
HK2 ab104836 Abcam 1:750 Colon tumour
PDK1 ab110025 Abcam 1:500 Stomach
ki67 M7249 Dako 1:50
CC3 9664 Cell Signaling 1:2000
Table 2. List of siRNAs used for gene silencing
Target siRNA Catalogue no.
SLC16A1 (MCT1) Hs_SLC16A1_6 siRNA SI032466362
Hs_SLC16A1_7 siRNA SI03246404
SLC16A3 (MCT4) Hs_SLC16A3_4 siRNA SI00720440
Hs_SLC16A3_5 siRNA SI04134774
All siRNAs were purchased from Qiagen.
qRT–PCR reactions were performed in triplicate in
384-well plates in cell lines. For each reaction, 1 ng
cDNA and 5 μl Fast SYBR Green Master Mix (Applied
Biosystems) were used in a 10 μl reaction volume.
mRNA expression was normalized to retention in endo-
plasmic reticulum 1 (RER1), using the 2−ΔΔCT method.
Ultrastructural studies
Samples were fixed in 2.5% glutaraldhyde in 0.1M
sodium cacodylate buffer, washed in the same buffer,
post-fixed in 1% OsO4 in buffer, dehydrated in ethanol
and embedded in Epon. Ultrathin sections were col-
lected on 300mesh copper grids and stained with 3%
aqueous uranyl acetate and lead citrate before being
observed in a transmission electron microscope (JEOL
100 CX II, Atlanta, Georgia, UK) operated at 60 kV.
Statistical analysis
Data from human tissue samples were analysed with
SPSS statistical software v. 18.0 (SPSS, IBM, London,
UK) using Pearson’s χ2 test, with the threshold for sig-
nificance being p≤ 0.05. For in vitro studies, GraphPad
Prism 5 software was used with Student’s t-test, consid-
ering significant values to be p≤ 0.05.
Ex vivo cultures
Samples from 10 wild-type animals, eight p53 trans-
genic mice with PIN lesions, five p53 transgenic
mice with undifferentiated adenocarcinoma, nine
PTEN-knockout mice with high-grade prostatic
intra-epithelial neoplasia (PIN), 12 PTEN-knockout
mice with micro-invasive adenocarcinoma and 14
PTEN-knockout mice with moderated and undifferen-
tiated adenocarcinoma for the four prostate lobes was
used. All experiments were conducted according to the
UK Home Office Regulations and protocols approved
under Project License No. 80-2435. Tumours were
collected and grown ex vivo. A solution containing
collagen, Matrigel and RPMI was prepared, added to
nylon sheets and incubated; 10ml 1% glutaraldehyde
in PBS was added to the sheets. After 1 h of incubation
at 4 ∘C, the nylon sheets were washed with PBS and
with 10% RPMI and incubated in 10% RPMI overnight.
Grids were plated in a six-well dish and the coated
nylon sheet placed on the grids. The well was filled with
medium containing gentamycin and treated with 50 μM
AR-C155858. Tumours were harvested 5 days later.
Results
The expression of glycolysis-related proteins
correlates with prostate cancer progression
in patients
Figure 1A shows the immunohistochemical expression
of MCT1, MCT4, glucose transporter 1 (GLUT1),
hexokinase 2 (HK2), lactate dehydrogenase 5 (LDH5),
pyruvate dehydrogenase kinase 1 (PDK1), carbonic
anhydrase IX (CAIX) and hypoxia-inducible factor
1α (HIF-1α) in benign prostate tissue (BT), prostatic
intra-epithelial neoplasia (PIN), localized prostate
tumour tissue (LT) and metastatic tumour tissue (MT).
In general, we observed that normal prostate epithe-
lium was either negative or weakly positive for MCT4
and glycolysis-related proteins, with the exception
of MCT1, whereas PIN lesions and adenocarcino-
mas showed intense staining in the majority of cases.
The most striking findings were obtained for MCT4
(Figure 1A, B1–B4) and CAIX (Figure 1A, G1–G4),
where an increase in the intensity and extension of the
staining from LT to MT was evident. Also, HIF-1α
only appeared in the nucleus of the cells in metastatic
samples (Figure 1A, H1–H4). Quantification of the
overall fraction of positive cases for the expression
of MCT1, MCT4 and glycolysis-related proteins
are shown in Figure 1B–D. In contrast to MCT1
(Figure 1B) we observed that the overall percentage of
positive cases for the expression of MCT4 (Figure 1C)
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Figure 1. MCTs and glycolysis-related protein expression is increased in PIN lesions, PCa and metastatic tissue. (A) Immunohistochemical
expression of MCT1, MCT4, GLUT1, HK2, LDH5, PDK1, CAIX and HIF-1α in benign tissue (BT), PIN lesions (PIN), tissue from localized
prostate tumour (LT) and metastatic tumour tissue (MT); magnification=×200). (B–D) Representation of positive cases for MCT1, MCT4
and glycolysis-related proteins in benign tissue, non-neoplastic tissue, PIN lesions, localized tumours and metastatic tumours (***p< 0.001)
and glycolysis-related proteins (Figure1D) increase
from non-neoplastic tissue to PIN lesions and localized
tumour, being most highly expressed in almost all
metastatic PCa tissues analysed.
The expression of MCT4 and proteins involved
in glycolytic metabolism is associated with poor
prognosis
We observed that MCT4 expression was associated
with poor prognosis, ie the presence of biochemical
recurrence after surgery based on protein expres-
sion (Figure 2A) and mRNA levels based on the
Glinsky dataset (Figure 2B) [24]. MCT4 protein expres-
sion was also associated with higher tumour stage
(Figure 2C). The expression of glycolysis-related pro-
teins in localized prostate tumours was associated with
important prognostic parameters, including Gleason
score (Figure 2D), presence of perineural invasion
(Figure 2E) and patient survival status (Figure 2F). To
corroborate our findings, we extended the analysis to
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on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org.uk www.thejournalofpathology.com
MCTs as targets for prostate cancer therapy 521
Figure 2. The expression of MCT4 and glycolysis-related proteins is associated with poor prognosis in PCa. (A) MCT4 expression at protein
level in human prostate cancer samples is associated with the presence of biochemical recurrence after surgery. (B) Kaplan–Meyer plots for
SLC16A3 (MCT4), based on Glinsky et al [24]; recursive partitioning was performed using a galaxy-based CRI Bioinformatics Core Facility
tool. (C) Pathological stage of the tumour (pT3); the expression of glycolysis-related proteins was associated with (D) cases of higher Gleason
score, (E) presence of perineural invasion and (F) prostate cancer-related death (***p< 0.001)
microarray profiling datasets of PCa tissues available
on the Oncomine database [25]. mRNA expression of
SLC16A1 (MCT1), SLC16A3 (MCT4) and a number
of glycolysis-related proteins was analysed in two inde-
pendent PCa datasets, Varambally et al [26] and Grasso
et al [27] (Figure 3A, B). We found that SLC16A1
(MCT1), SLC16A3 (MCT4) and the glycolysis-related
proteins were significantly over-expressed in primary
and metastatic PCa. After this observation we clustered
genes co-expressed with SLC16A1 and SLC16A3 in
prostate tissues available at the Cancer Genome Atlas
(TCGA) database by their functional role and impor-
tance in signal transduction pathways, using the DAVID
bioinformatics tool (Figure 3C–F). We found that the
majority of genes co-expressed with SLC16A1 were
genes correlated with normal biological processes of
cells, while genes co-expressed with SLC16A3 were
functionally clustered in the categories considered
relevant for tumour progression and development.
A sub-analysis of signalling pathways revealed that
SLC16A3-co-expressed genes are grouped in pathways
associated with higher aggressiveness, viz immune
response and regulation of cell proliferation and migra-
tion (Figure 3F). Importantly, in silico analysis indicates
inverse correlation between SLC16A3 and the epithe-
lial markers E-cadherin, NKX3.1 and TP53INP1, and
a direct correlation with MMP14, involved in the
epithelial–mesenchymal transition (EMT) process
(Figure 3G–J), suggesting a possible role in metastasis.
Different models of prostate cancer progression
recapitulate expression profiles of human PCa
tissues and exhibit a distinct metabolic phenotype
MCT4 expression was more evident at the plasma mem-
brane of PC3 cells than in LNCaP cells, whereas MCT1
staining was similar in both models (Figure 4A). mRNA
levels for MCT1 and MCT4 were readily detectable
by qRT–PCR in cell lines (Figure 4B–C) and both
MCT1 and MCT4 expression varied depending upon
the cell line. MCT4 mRNA levels clearly show a strong
correlation with the aggressiveness of the PCa cell
model (Figure 4C). Also, there was a clear differ-
ence in metabolic behaviour between the low- and
high-tumourigenic lines. PC3 and DU145 cells exhib-
ited higher levels of glucose consumption (Figure 4D)
and lactate production (Figure 4E) when compared to
22RV1 and LNCaP cells. Additionally, we measured the
oxygen consumption rate (OCR) (Figure 4F) with simul-
taneous measurement of the extracellular acidification
rate (ECAR) (Figure 4G). These results interestingly
showed that although the highly metastatic model PC3
cells exhibited higher levels of ECAR, it also showed an
increased oxygen consumption rate (OCR) compared to
the lower tumourigenic LNCaP cells.
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Figure 3. Analysis of microarray expression data for SLC16A1, SLC16A3 and glycolysis-related genes from the Oncomine database.
Expression is presented for two different datasets, (A) Varambally et al and (B) Grasso et al, representing different detection probes. (C–F)
Expression profiles of the co-expressed genes SLC16A1 and SLC16A3 were obtained from the Cancer Genome Atlas (TCGA) and clustered by
functional role and signalling pathways, using the DAVID in silico tool: the left panels (C, E) represent the functional clusters organized by
enrichment score, and the right panels (D, F) represent the signalling pathway analysis. SLC16A3 co-expressed genes are associated with
pathways involved in tumour aggressiveness, viz in immune cell response, positive cell cycle regulation, cell motility and chemotaxis. (G–J)
In silico analysis indicates an inverse correlation between SLC16A3 and the epithelial markers E-cadherin (CDH1) (G), NKX3.1 (H), TP53 (I)
and a direct correlation with several genes involved in the epithelial–mesenchymal transition (EMT), such as MMP14 (J)
Our previous observation that, while PC3 cells
exhibit higher levels of glucose consumption and
lactate production as well as higher ECAR rates,
they also show higher OCR levels, led us to analyse
different cell lines at the ultrastructural level to look
for differences at the mitochondrion level. Electron
micrographs of LNCaP (Figure 4H), PC3 (Figure 4I)
and two human PCa samples from localized tumour
(TT) (Figure 4J, K) are represented. We observed that in
both LNCaP cells and human samples (Figure 4H, J, K),
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Figure 4. Distinct in vitro models of PCa cell lines exhibit different metabolic behaviours. (A) Immunohistochemical expression of MCT1 and
MCT4 in distinct in vitro models of prostate cancer progression. (B, C) mRNA expression levels of MCT1 and MCT4 in prostate-derived cell
lines; for RNA quantification, n= 3; data expressed as± SD (n= 3); ***p< 0.001. (D–G) Metabolic characterization of prostate cell lines,
based on (D) glucose consumption and (E) lactate production; (F) oxygen consumption rates (OCRs) and (G) extracellular acidification rates
(ECAR) are also represented for these different models of prostate cancer progression. (H, I) Electron micrographs of LNCaP and PC3 cell
lines: (H) in LNCaP, mitochondria (M) and lipidic inclusions (Li) were observed distributed randomly in the cytoplasm of cells; (I) in PC3
cells, small, atypical mitochondria (M) were observed and no lipidic inclusions were seen; magnification=×16 000). (J, K) Cells collected
from tumour localized to the prostate showed structures similar to those of LNCaPs (magnification=×16 000). (L–Q) Analysis of Complex
I activity in LNCaP, 22RV1 and PC3 PCa cells: activity mOD (milli-units of optical density) was measured at 450 nm; data correspond to two
biological replicates performed in duplicate; *p< 0.05: (L, M) analysis of global ATP levels; data correspond to three biological experiments,
each performed in triplicate; data were subjected to one-way ANOVA and Tukey test; (N) western blot analysis for UCP-2 protein, β-actin
as an exogenous control and TOM-20 as a control for mitochondrial loading; a representative immunoblot of two experiments is shown; (O)
quantification of UCP-2 protein in the cell lines, expressed as density of UCP-2 band/density of TOM-20; (P) quantification of UCP-2 protein
in the cell lines, expressed as density of UCP-2 band/density of β-actin; (Q) quantification of TOM-20 protein in the cell lines, expressed as
density of TOM-20 band/density of β-actin; data were subjected to one-way ANOVA and a posterior Tukey test; *p< 0.01
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the cells were packed with lipid bodies. Also, there was
a difference in mitochondrial morphology, ie the mito-
chondria of PC3 cells were smaller and had an atrophic
appearance, with sparse and poorly formed cristae.
Investigation of Complex I activity in prostate cell
lines showed that PC3 cells have increased activity
(Figure 4L). However, this increased Complex I activ-
ity was not reflected in global cellular ATP levels
(Figure 4M). This suggests that the proton electrochem-
ical gradient across the inner mitochondrial membrane
(IMM) was being dissipated and not utilized for ATP
production. In fact, when we looked at the expres-
sion levels of the mitochondrial uncoupling protein 2
(UCP2), we verified that it was significantly higher in
PC3 cells, using both β-actin (p= 0.02) as the total
protein loading control, and the translocase of outer
mitochondrial membrane 20 homologue (TOMM20;
p< 0.01) as a mitochondrial protein loading control
(Figure 4N–Q). Taken together, these observations point
to inefficient respiration in the highly metastatic model,
ie PC3 compared to the low metastatic models.
SLC16A1 and SLC16A3 gene expression is increased
under hypoxia but independent of androgen
stimulation
Since the androgen receptor (AR) is an important regula-
tor of metabolic pathways in PCa, regulating the expres-
sion of various genes involved in metabolism [28], we
sought to determine potential cross-regulation between
MCTs and AR signalling. We found that MCT1 lev-
els were higher in PC3 and LNCaP cells compared to
DU145 and 22RV1 cell lines (Figure 5A). MCT4 pro-
tein was only present in the AR-negative cells, PC3
and DU145 (Figure 5B). In LNCaP cells treated with
the synthetic androgen R1881, no major changes were
observed for MCT1 and MCT4 mRNA expression lev-
els during up to 24 h of treatment (Figure 5C, D).
While MCT1 has emerged as a new anticancer target
and a first MCT1 inhibitor is currently entering clin-
ical trials [29,30], little is known about its regulation
by typical parameters of the tumour microenvironment.
Figure 5E–H shows the expression levels of MCTs
in LNCaP and PC3 cell lines when grown under dif-
ferent oxygen conditions. The results clearly show an
increase in MCTs expression with hypoxia, a typical
feature of the tumour microenvironment. Figure 5K,
L, shows a comparison of SLC16A1 and SLC16A3
peaks from ChIP-seq in LNCaP cell lines growing under
different oxygen conditions. While no HIF-1α binding
peaks are seen for SLC16A1 (Figure 5I), there is a clear
HIF1A binding peak upstream of the SLC16A3 locus
(Figure 5J). Figure 5M shows a Venn diagram demon-
strating the overlap between groups of genes expressed
by LNCaP cells under different conditions (M Tran,
unpublished results). It is interesting to observe that
SLC16A3, LDHA, PDK1 and CA9, previously associ-
ated with poor prognosis, appear in the group of genes
expressed when hypoxia is present, with or without
androgen stimulation.
Silencing of MCTs affects the growth kinetics
of prostate cell lines and decreases the expression
of genes associated with poor prognosis in PCa
Figure 6 shows that in different models of PCa progres-
sion, silencing of MCTs produces differential effects.
Successful knockdown was validated using qRT–PCR
3 days after transfection (Figure 6A–C). We observed
that, under normoxia, the silencing of MCT1 caused a
significant decrease in the viability of almost all prostate
cell lines, whereas silencing of MCT4 mostly affected
the viability of the highly tumourigenic models, C4-2B
and PC3 cells (Figure 6D). Due to the already men-
tioned importance of hypoxia with subsequent activation
of HIF-1α and the implication in tumour metabolism,
plus the observation thatMCT4 mRNA and protein lev-
els clearly increase in hypoxic conditions, we assessed
the effects of MCTs knockdown under hypoxic condi-
tions (Figure 6E). These results demonstrate that the sen-
sitivity of cells to MCT4 knockdown is increased under
these conditions. In addition, contrary to the results seen
with normoxia, MCT4 knockdown under hypoxia was
shown to also decrease the viability of LNCaP cells
(Figure 6E).
In order to define the nature of the response to
silencing of MCT1 and MCT4, the cell-cycle profile of
cells cultured under normoxic or hypoxic conditions
were determined by flow cytometry (only data for
normoxic conditions are presented, since the results
were similar). A significant increase in the proportion
of cells with sub-G1 DNA content was detected fol-
lowing MCT1 knockdown in PC3 cells (Figure 6F).
After MCT4 knockdown, the cell-cycle profile of cells
was also affected, with a clear increase in the sub-
population of cells in S phase under both growing
conditions (Figure 6G). Also, in terms of metabolic
phenotype, MCT1 knockdown decreased the ECAR
levels in LNCaP cells (Figure 6I), whereas MCT4
knockdown increased OCR in PC3 cells under nor-
moxia (Figure 6J). Also, ECAR levels decreased in PC3
cells when MCT1 and MCT4 were silenced, even under
normoxia (Figure 6K).
Following this observation, we used qRT–PCR to
compare mRNA levels of the metabolism-related pro-
teins, namely those previously linked to a poorer out-
come, before and after MCT1 and MCT4 knockdown
(Figure 6L–Q). We found that, under normal oxygen
levels, MCT1 knockdown decreased PDK1 and CA9 in
LNCaP cells and LDHA and CA9 in PC3 cells, whereas
under the same conditions, MCT4 knockdown did not
affect PDK1 and LDHA levels and actually resulted in
an increase in CA9 levels. In contrast, when cells were
grown under low-oxygen conditions,MCT1 knockdown
caused a decrease in PDK1, LDHA and CA9 levels in
LNCaP and PC3 cells. The same was observed when
MCT4was silenced in PC3 cell lines.MCT4 knockdown
also caused a drastic increase in CA9 levels in PC3 cells.
These results show a clearly distinct effect caused by
MCTs knockdown in PCa cells under different microen-
vironmental conditions.
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Figure 5. (A, B) Western blot analysis of MCT1 and MCT4, showing different levels of expression in different prostate cancer cell lines.
(C–F) Effect of androgen stimulation and inhibition on MCTs expression: (C, D) plots from the expression array with androgen treatment
time-course; (E–H) effect of hypoxic conditions (1% O2) on MCTs expression; levels of MCT1 (E, F) and MCT4 (G, H) in PCa cells under
normoxic (NX) and hypoxic (HX) conditions; aata expressed as± SD; n= 3; *p< 0.05. (I, J) Integrated Genome Browser view of ChIP-Seq
enrichment profiles of SLC16A1 and SLC16A3 in LNCaP cell lines. (K) Venn diagram showing the overlap between genes expressed by LNCaP
cell lines under different oxygen and hormone conditions
MCT1 and MCT4 expression is high in PTEN-
negative and pRb p53-negative tumours and the
use of AR-C155858 decreases proliferation
and increases cell death in mouse tumours
Using transgenic mouse models, we observed that
SLC16A1 and SLC16A3 were both over-expressed
from normal mouse prostate to PIN lesions and medium
and advanced PTEN-null tumours (Figure7A, B). Also,
tumours derived from p53 mice expressed high levels
of SLC16A1 and SLC16A3. Interestingly, only PIN
lesions from the PTEN-null models, but not the p53-null
model, expressed higher levels of SLC16A3 compared
to the control mice. This is particularly interesting,
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Figure 6. MCT knockdown affects cell viability and metabolic behaviour of PCa cell lines. (A–C) LNCaP and PC3 cells were transfected
with two different combinations of siRNA directed against MCT1; PC3 cells were also transfected with two different combinations of siRNA
directed against MCT4; successful knockdown was validated using qRT–PCR, 3 days after transfection (n= 4). (D–E) Effects ofMCT1 (siRNA
#6+#7) andMCT4 (siRNA #4+#5) knockdown on cell growth: (D) effect ofMCT1 knockdown andMCT4 on different prostate cancer cell
lines when compared to the scrambled siRNA after 48 h; (E) effect of MCT1 and MCT4 inhibition on cell growth under hypoxic conditions;
***p< 0.001. (F–G) Percentage of PC3 cells in G0 –G1, S and G2 –M fraction whenMCT1 (F) orMCT4 (G) are silenced compared to scrambled
(Scr); data are expressed as mean± SD (n= 2); ***p< 0.001. (H–K) Oxygen consumption rates (OCRs) and extracellular acidification rates
(ECARs) are shown for LNCaP and PC3 cell lines under control conditions (UT) and when MCT1 (siMCT1) or MCT4 (siMCT4) are silenced;
*p< 0.05. (L–Q) To assess the effects of MCT1 and MCT4 knockdown on HIF-target genes, LNCaP and PC3 cells were transfected with
siRNAs and grown for 3 days: mRNA expression was assessed by qRT–PCR; values are depicted relative to vehicle control for each siRNA
(n= 4); HX, hypoxia; NX, normoxia
since it is known that only the PIN lesions derived from
PTEN mice are able to progress to PCa, in contrast to
PIN derived from p53 (Figure 7A, B).
To achieve a more realistic insight into the efficacy
of MCTs inhibition in PCa, we used AR-C155858.
The reason for selecting this compound relies on
the fact that this small molecule is described as
isoform-specific for MCT1 and is now under clini-
cal trials [29], whereas so far there are no specific
inhibitors for MCT4. The binding site for AR-C155858
is contained within the C-terminal half of MCT1
and involves transmembrane (TM) domains 7–10 [31].
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Figure 7. (A, B) SLC16A1 (MCT1) and SLC16A3 (MCT4) mRNA expression levels in tissue samples derived from transgenic mice; expression
levels were assessed in PTEN- and p53pRb-negative transgenic mice. Normal prostate, precursor lesions (PIN) derived from both PTEN- and
p53pRb-negative mice, micro-invasive and well-differentiated adenocarcinoma (MED PTEN), moderate and undifferentiated adenocarcino-
mas (HIGH PTEN) and undifferentiated adenocarcinoma in p53pRb-negative (TUMOUR p53) were considered. (C, D) Immunohistochemistry
showing ki67 (C) and cleaved caspase 3 staining (D) in mouse prostate. Benign glands and PTEN-negative-derived tumours are shown,
with and without treatment with AR-C155858; bars= 200 μm. (E, F) A total number of 30–50 randomly chosen images were used for the
analysis of ki67 and CC3 staining in benign tissue (BT) and tumour tissue (TT); (E) percentage of positive nuclei for ki67 expression in benign
tissue (BT) and tumour tissue (TT), with and without treatment; (F) percentage of nuclei positive for CC3 expression in benign tissue (BT)
and tumour tissue (TT), with and without treatment
Tumours from PTEN-negative mice were treated ex vivo
with AR-C155858 for 5 days, fixed and the presence of
cleaved caspase-3 (CC3) and KI67 levels were assessed
by immunohistochemistry (IHC). Figure 7C, D shows
expression of KI67 (C) and CC3 (D). We have clearly
observed that benign glands were not affected by the
drug. Proliferating cells are seen in benign glands in both
the presence and absence of AR-C155858. However, in
tumours a decrease in KI67 expression was observed
following treatment (Figure 7C). Regarding CC3, the
benign glands were not affected (just 1% of apoptotic
cells was verified) in contrast to PTEN tumours which,
when treated with the drug, showed high expression of
CC3 with an evident effect not only in the epithelial
cells but also in the reactive stroma (Figure 7D). The
quantification of KI-67- and CC3-positive nuclei for
tumour tissue samples (TT) and benign tissue (BT),
with and without treatment (untreated, UT) is shown in
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Figure 7E, F. This confirmed that AR-C155858 caused
a decrease in proliferation (p< 0.0001) and increased
apoptosis (p< 0.0001) in tumour tissues, with no signif-
icant effect on benign tissue (p= 0.1086 and p= 0.6993,
respectively).
Discussion
A fundamental challenge in PCa research involves
understanding the transition of cancer cells from andro-
gen dependence to androgen independence. Hypoxia
is thought to participate in androgen resistance under
conditions of androgen deprivation via the induction of
androgen hypersensitivity [32] and the amplification of
androgen receptor activity [33]. While numerous studies
have investigated the involvement of altered cellular
metabolism in various tumours, little is known about the
metabolic alterations during PCa progression. Ranas-
inghe et al.(34) linked hypoxia with aggressiveness
and metastasis in PCa. However, how the expression
of proteins involved in cellular energetic metabolism
is altered during prostate malignant transformation and
progression, in addition to the significance of their
expression, is largely unknown.
We consistently showed that proteins involved in the
glycolytic pathway aberrantly over-expressed across
prostate malignancy, associated with both prostate
metastatic tissue and poor prognosis. Accordingly, the
highly metastatic models were shown to consume more
glucose, with consequent lactate production, compared
to the poorly metastatic models. Additionally, we found
evidence for less energetically efficient respiration in the
high metastatic lines that over-express UCP2 protein,
indicating a coupling defect in oxidative phosphoryla-
tion in these cells. These results support the concept that
PCa does not fit the traditional model of a metabolic
switch to glycolysis from non-malignant to malignant
cells, but instead this metabolic switch is more likely to
be involved in advanced stages of the disease.
Following these observations, we found that MCT4
expression at both gene and protein levels was always
associated with malignancy. Both isoforms were shown
to increase under hypoxic conditions; however, only
a direct link for HIF-1α and MCT4 could be pro-
vided, with the existence of HIF-1α binding sites present
upstream of the SLC16A3 gene. Consistent with the idea
of a metabolic phenotype stimulated by hypoxic condi-
tions that can allow the tumour to grow in the absence
of androgens, our expression arrays showed that the
proteins previously associated with poor prognosis in
human tumour samples were the ones encoded by genes
that were up-regulated in low-oxygen conditions, inde-
pendent of the presence of androgens. Silencing MCT4
was shown to be effective in PCa cell lines when under
hypoxia. In contrast, MCT1 silencing was shown to
be effective when the cells were growing under both
conditions.
Importantly, the metabolic phenotype of PCa cells
was clearly affected after MCTs silencing, indicating
a role for MCTs as metabolic modulators. One of the
most interesting results observed was that MCTs inhi-
bition was able to affect the expression levels of the
glycolysis-related proteins previously associated with
poor prognosis in PCa. Surprisingly, an increase in CA9
was observed whenMCT4was silenced. We believe this
could be due to a possible interaction between CAIX and
MCT4 [34] that is disrupted byMCT4 knockdown.
In accordance with observations in human samples,
MCT4 levels increase in the transgenic mouse model
tumours. However, MCT4 levels were already high
in mouse PIN lesions; this high level was not found
in human models. Considering that most PIN lesions
derived from PTEN-transgenic mice will progress
to tumour, in contrast to PIN lesions derived from the
p53-transgenic models [35], the high levels of SLC16A3
only in PIN lesions from PTEN models corroborates
once more the involvement of MCT4 in disease
progression.
MCTs have been extensively described at the plasma
membrane of solid tumours as major players in the
acid-resistant phenotype of tumour cells, and as attrac-
tive targets for cancer therapy, alone or in combination
with other drugs targeting metabolism [36–38]. How-
ever, their role in tumours that do not rely primarily
on glycolysis, such as prostate cancer, has been largely
neglected. The use of MCT1 inhibitor AR-C155858
revealed the potential of this target as a specific
anti-tumour therapy affecting apoptosis and prolif-
eration in tumours, with no adverse effects seen in
benign glands. In addition to the promising results
shown with MCT1 inhibition, we hypothesize that
the function of MCT4 is also of great importance for
pH regulation and growth in the context of in vivo
metabolism when tumour cells are exposed to a hypoxic
microenvironment, and therefore therapies targeting
MCT4 specifically should also be explored. To the best
of our knowledge, this is the largest study demonstrat-
ing the metabolic heterogeneity of PCa using human
samples, with clinical–pathological significance, and
demonstrates a role for glycolysis-associated proteins
as putative prognostic biomarkers in PCa. Our study
also positionsMCT4 as a putative prognostic biomarker
in PCa, and bothMCT1 andMCT4 isoforms as possible
therapeutic targets for advanced tumours in patients.
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